A Phase 3 Randomized, Observer-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Adults 18 through 55 years of Age.

Project: Research project

Project Details

StatusActive
Effective start/end date3/11/213/10/25

Funding

  • Pfizer, Inc.: $12,090.00